Generation of hypoallergenic neoglycoconjugates for dendritic cell targeted vaccination: A novel tool for specific immunotherapy  by Weinberger, Esther E. et al.
Journal of Controlled Release 165 (2013) 101–109
Contents lists available at SciVerse ScienceDirect
Journal of Controlled Release
j ourna l homepage: www.e lsev ie r .com/ locate / jconre lGeneration of hypoallergenic neoglycoconjugates for dendritic cell targeted
vaccination: A novel tool for speciﬁc immunotherapy
Esther E. Weinberger a, Martin Himly a, Julia Myschik b, Michael Hauser a, Friedrich Altmann c,
Almedina Isakovic a, Sandra Scheiblhofer a, Josef Thalhamer a,⁎, Richard Weiss a
a Department of Molecular Biology, University of Salzburg, 5020 Salzburg, Austria
b Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-University Munich, 81377 Munich, Germany
c Department of Biochemistry, University of Natural Resources and Life Sciences, 1190 Vienna, Austria⁎ Corresponding author. Tel.: +43 662 8044 5737; fa
E-mail address: Josef.Thalhamer@sbg.ac.at (J. Thalha
0168-3659 © 2012 Elsevier B.V.
http://dx.doi.org/10.1016/j.jconrel.2012.11.002
Open access under CC BY-NCa b s t r a c ta r t i c l e i n f oArticle history:
Received 6 August 2012
Accepted 1 November 2012
Available online 10 November 2012
Keywords:
Targeting
C type lectin receptors
Carbohydrates
Hypoallergen
Speciﬁc immunotherapyThe incidence of allergic disorders and asthma continuously increased over the past decades, consuming a
considerable proportion of the health care budget. Allergen-speciﬁc subcutaneous immunotherapy represents
the only intervention treating the underlying causes of type I allergies, but still suffers fromunwanted side effects
and low compliance. There is an urgent need for novel approaches improving safety and efﬁcacy of this therapy.
In the present studywe investigated carbohydrate-mediated targeting of allergens to dermal antigen-presenting
cells and its inﬂuence on immunogenicity and allergenicity. Mannan, high (40 kDa) and low (6 kDa) molecular
weight dextran, and maltodextrin were covalently attached to ovalbumin and papain via mild carbohydrate
oxidation resulting in neoglycocomplexes of various sizes. In particular, mannan-conjugates were efﬁciently
taken up by dendritic cells in vivo leading to elevated humoral immune responses against the protein moiety
and a shift from IgE to IgG. Beyond providing an adjuvant effect, papain glycocomplexes also proved to mask
B-cell epitopes, thus rendering the allergen derivative hypoallergenic.
The present data demonstrate that carbohydrate-modiﬁed allergens combine targeting of antigen presenting
cells with hypoallergenicity, offering the potential for low dose allergen-speciﬁc immunotherapy while
concomitantly reducing the risk of side effects.
© 2012 Elsevier B.V. Open access under CC BY-NC-ND license. 1. Introduction
Targeting antigens to endocytic receptors on antigen presenting cells
(APCs) represents an attractive approach to enhance vaccine efﬁcacy.
In particular, the mannose receptor (MR) and related C-type lectin
receptor (CLR) family members such as DEC205, DC-SIGN, MGL,
Langerin, Dectin-1, and Mincle demonstrated excellent carbohydrate
antigen-capturing and processing capabilities [1–5]. They are preferen-
tially expressed on APCs, albeit to a type-dependent and varying degree
[6]. Particularly immature dendritic cells (DCs) express a large panel of
lectins, linked to their important function of sensing and capturing
self-, as well as non-self-antigens for processing and presentation onto
MHC molecules, thus inducing antigen-speciﬁc T-cell activation [7,8].
As pattern recognition receptors, they link innate and adaptive immune
responses. Especially the MR has demonstrated effective induction
of cellular as well as humoral immune responses, and increased atten-
tion is paid to the exploitation of MR- and other CLR-targeted vaccines
for cancer, infectious diseases, and for speciﬁc tolerance induction inx: +43 662 8044 5751.
mer).
-ND license. autoimmune diseases [9]. In the present study, we evaluated the
immunostimulatory capacity of neoglycoallergens generated by covalent
carbohydrate attachment to proteins, and their potential for speciﬁc
immunotherapy (SIT). SIT represents the only therapeutic intervention
for patients suffering from type I allergy, i.e. allergic rhinoconjunctivitis,
venom hypersensitivity, some drug allergies, or mild bronchial asthma.
Themost commonlyused route of desensitization is subcutaneous immu-
notherapy (SCIT) by needle injection. SCIT harbors several local and
systemic side effects, including urticaria, asthma attacks, and anaphylaxis
[10] that vary in incidence from 0.1 to 5% of patients, also depending on
the severity of disease [11]. The alarming trend of vastly increasing inci-
dences of allergy and asthma, that already affect about one third of the
general population in industrialized countries, requires the development
of novel approaches improving the efﬁcacy anddecreasing the side effects
of SCIT [12].
In the present study, we used mild carbohydrate oxidation for
covalent attachment of mannan, a cell wall component of Saccharomyces
cerevisiae, to ovalbumin (Ova) and papain (Pap). The complex-forming
capacities of both proteins were analyzed and compared to other carbo-
hydrate structures, differing in size and origin. The neoglycocomplexes
demonstrated excellent DC-targeting potential as assessed by ﬂow
cytometric analysis of antigen-loaded DCs in the draining lymph nodes,
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neoglycocomplexes were able to enhance immunogenicity while con-
comitantly suppressing IgE induction, and proved to be hypoallergenic,
an important requirement for safer SCIT.
2. Materials and methods
2.1. Materials
Mannan (MN) from S. cerevisiae (average molecular weight approx.
46 kDa), dextran (Dex) from Leuconostoc mesenteroides (~40 kDa), dex-
tran from Leuconostoc spp. (~6 kDa), and maltodextrin (MD; dextrose
equivalent 4.0–7.0, ~3.6 kDa), ovalbumin (Ova) from chicken egg
white (gradeV), concanavalin A (ConA), protease inhibitor E64, ethylene
glycol, sodium borohydride (NaBH4), L-cysteine and sodium periodate
(NaIO4) were purchased from Sigma Aldrich (Deisenhofen, Germany).
Papain (Pap) from Carica papaya was purchased from Roth (Karlsruhe,
Germany). Sodium cyanoborohydride (NaCNBH3) was purchased from
Fluka Chemie AG (Buchs, Switzerland). pHrodo was obtained from
Invitrogen (Darmstadt, Germany). All other reagents were of analytical
grade. Pharmacological inactivation of papain using E64 was performed
by the addition of 5 mM cysteine-HCl, followed by the addition of E64
in a 100-fold molar excess relative to papain. After 2 h incubation,
inactivated papain was dialyzed for removal of excess E64, protein con-
centrations were calculated by OD280 measurement and activity was
tested by immunoglobulin cleavage [13].
2.2. Generation of carbohydrate — protein conjugates
Conjugates were generated by an adapted protocol based on a publi-
cation ofMislovicova et al. [14]. Brieﬂy, 100 mg ofmannanwas dissolved
in 1 mL (MN1), 2 mL (MN2), 3.5 mL (MN3), or 10 mL (MN4) of an aque-
ous solution of 50 mM sodium periodate (NaIO4) and vigorously stirred
in the dark at 4 °C for 1 h. To stop oxidation, 1 mL ethylene glycol was
added and again stirred in the dark for 1 h at 4 °C. Lowmolecularweight
components were then removed from the reaction mixture by dialysis
against distilled H2O at 4 °C in the dark (Spectra/Por dialysis tubing,
MWCO 6000–8000, Spectrum Europe B.V., Breda, The Netherlands).
The oxidized mannan was then lyophilized and kept at −20 °C. To
ensure aldehyde group incorporation, aldehydes were quantiﬁed with
the amplite colorimetric aldehyde quantitation kit (Biomol, Hamburg,
Germany). For protein coupling, the oxidizedmannanwas reconstituted
in 10 mL of a 50 mM sodium phosphate buffer (pH 7) and added to
10 mL of the protein of interest (10 g/L Ova or Pap) dissolved in the
same buffer. Additionally, 6 mL of a freshly prepared NaCNBH3 solution
(10 g/L in 50 mM sodium phosphate buffer, pH 7) was added and the
reaction mixture was kept in the dark and stirred at RT for 24 h. To
stop the coupling reaction, 1300 μL of a NaBH4 solution (5 g/L in
50 mMborate buffer, pH 9.5)were added to reduce any remaining alde-
hyde groups. The reaction was stirred in the dark for 6 h at RT and after-
wards dialyzed against H2O. Protein–carbohydrate conjugateswere then
lyophilized and kept at−20 °C for long time storage.
To analyze coupling homogeneity, samples were assessed by reduc-
ing SDS PAGE (10%) at 140 V for 2 h and stained with a Pro-Q Emerald
300 glycoprotein staining kit (Invitrogen, Carlsbad, CA, USA) for carbo-
hydrate detection, as well as colloidal coomassie for protein visualiza-
tion. Uncoupled carbohydrates were removed by Vivapure Q Maxi H
ion exchange spin columns (Sartorius Mechatronics Austria, Vienna,
Austria). Carbohydrate to protein ratio was analyzed by phenol-
sulfuric acid method [15] and OD280 absorbance, respectively.
2.3. Mannan-binding lectin assay
Carbohydrate integrity was analyzed via a precipitation assay using
mannan-binding lectin (MBL). In short, 500 μL of increasing amounts of
mannan or conjugate [25–400 μg/mL] in assay buffer (50 mM sodiumphosphate, 0.1 M NaCl, 0.1 mM CaCl2, 0.1 mM MnCl2×4H2O, pH 7)
were added to 500 μL ConA [230 μg/mL] in assay buffer. The reaction
mixtures were stirred at 25 °C for 2 h. Afterwards, samples were
centrifuged for 10 min at 8400 g and washed twice with 1 mL 1 M
NaCl, and the pellet was dissolved in 100 μL 50 mM sodium phosphate
(pH 10.5). Turbidity measurement was performed on an Inﬁnite M200
Pro plate reader (Tecan, Salzburg, Austria) at 405 nm in NUNC 96 well
plates (Thermo Scientiﬁc, Langenselbold, Germany).
2.4. Light obscuration and turbidity measurements
Light obscuration measurements were conducted with a PAMAS-
SVSS-C Sensor HCB-LD 25/25 (Partikelmess- und Analysensysteme
GmbH, Rutesheim, Germany) to quantify particles≥1 μm. Three aliquots
of 0.3 mL of each sample were analyzed. Turbidity was measured by 90°
light scattering at λ=860 nm using a NEPHLA turbidimeter (Dr. Lange,
Düsseldorf, Germany). Approximately 1.8 mLof theﬁnal sampleswas an-
alyzed according to the European Pharmacopoeia. The results are
reported in formazine nephelometric units (FNU).
2.5. Size exclusion chromatography (SEC) and dynamic light scattering (DLS)
Size-exclusion chromatography was performed using a 26/60 mm
Sephacryl S-300 High Resolution column (GE Healthcare, Uppsala,
Sweden) on a LC system (pump purchased from Bischoff, Leonberg,
Germany; injector type 9125 purchased from Rheodyne, Wertheim-
Mondfeld, Germany) equipped with a built-in SunChrom Spectraﬂow
500 UV–VIS detector (SunChrom, Friedrichsdorf, Germany) for
neoglycocomplex size characterization. Samples were analyzed in dupli-
cates using Chromeleon 6.70 SP5. For high-molecular weight MN–Ova
preparation, a 10/300 mm Superdex 75 GL column (GE Healthcare, Upp-
sala, Sweden) on an ÄKTA FPLC chromatography system was employed
and data was processed using UNICORN 5.11.
The aggregation behavior in solution was analyzed by dynamic light
scattering (DLS802; Viscotek) at 1.2–5 mg/mL for proteins and
neoglycocomplexes or 10 mg/mL for carbohydrates in PBS, pH 7 after
10 min centrifugation at 14,000 g. Data were accumulated for 10×10 s
and the correlation function was ﬁtted into the combined data curve,
from which the intensity distribution was calculated using solvent set-
tings for water. The calculated intensity distribution was weighted statis-
tically by mass using the mass model for proteins (OmniSizeTM)
displaying molecular size RH (nm) and polydispersity (% RSD) [16].
2.6. Mice and immunizations
Female, 6–10 week-old BALB/c mice were obtained from Charles
River Laboratories (Sulzfeld, Germany) and maintained at the animal
facility of the University of Salzburg according to the local guidelines
for animal care. Animal experiments were performed in accordance
with local guidelines approved by the Austrian Ministry of Science
(permit number: GZ 66.012/0004-II/10b/2010).
BALB/c mice (n=5) were immunized intradermally into the ear
pinnae with 1 μg Ova, Pap, protease-inactivated Pap (inactivated with
E64), or the respective neoglycoantigens (MN–Ova, MN–Pap, Dex–Pap
and MD–Pap), dissolved in 80 μL sterile PBS on days 0, 14, and 28. The
solution was aliquoted and 40 μL was applied to each of the two pinnae
of the animals by needle injection. Blood samples were taken on days
12, 26, and 40. Mice were sacriﬁced on day 56 when blood samples
were taken and splenocytes were prepared. Antibody levels were
evaluated via a luminometric ELISA assay at indicated serum dilutions
lying within the linear range of the assay. Biologically functional IgE
was assessed by an in vitro basophil release assay and basophil activa-
tion assay. Splenocytes were cultured and cellular proliferation by H3-
Thymidin uptake, as well as cytokine secretion upon allergen re-
challenge (ELISPOT) was measured. A more detailed description of
these assays can be found elsewhere [17].
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cells
The IgE-crosslinking capacity of the neoglycocomplexes was mea-
sured via degranulation assay using rat basophil leukemia RBL-2H3
cells. Brieﬂy, RBL-2H3 cells were passively sensitized with IgE-
containing sera from Ova- or Pap-sensitized BALB/c mice. After
washing, degranulationwas triggered by the addition of serial dilutions
of the respective neoglycocomplexes, or the unmodiﬁed allergens as
reference, and beta-hexosaminidase release was measured by enzy-
matic cleavage of the ﬂuorogenic substrate 4-methylumbelliferyl-N-
acetyl-b-D-glucosaminide. Data are expressed as percentage of total
release after Triton X-100 treatment [17].
2.8. Basophil activation assay
Basophil activation of murine whole blood samples was analyzed
according to Torrero et al. [18]. Whole blood (50 μL) was diluted with
50 μL RPMI 1640 (PAA, Pasching, Austria) containing 200 μg/mL hepa-
rin, and incubated with 40 μg/mL of the respective antigen (Ova or
E64-inactivated Pap), with 2 μg/mL anti-IgE (clone 23G3, eBioscience)
as positive control, or left untreated as negative control for 2 h at
37 °C and 7% CO2. Cells were washed and centrifuged at 500 g for
5 min prior to surface staining using anti-CD200R3 (clone Ba103,
Hycult biotech), anti-CD49b (clone DX5, BioLegend), anti-CD200R
(clone OX110, eBioscience), and anti-CD45 (clone 30-F11, BD biosci-
ences). After incubation, cells were washed twice with PBS/1%BSA/
2 mM EDTA and analyzed on a FACSCanto II ﬂow cytometer using
FACSDiva Software (BD Biosciences).
2.9. Flow cytometric analysis and histology of antigen-loaded draining
lymph node DCs
Mice were immunized intradermally into the ear pinnae with 50 μg
pHrodo-labeled antigen (Ova, Pap, MN–Ova, MN–Pap or Dex–Pap)
dissolved in 20 μL sterile PBS. The solution was aliquoted and 10 μL
was applied to each of the two pinnae of the animal. 24 h later, antigen
uptake and transport to the ear-draining lymph nodes (dLNs) by resi-
dent DCs were characterized by FACS analysis. Pinna-dLN nodes were
prepared [19], pooled for each group and surface stained using
anti-MHCII (clone M5/114, BD Pharmingen), anti-CD11b (clone M1/
70, BioLegend), anti-CD11c (clone N418, eBioscience), and anti-CD8α
(clone 53-6.7, eBioscience). For ﬂuorescent microscopy, mice received
10 μg pHrodo-labeled MN–Ova into the ear pinna and dLNs were
excised 30 min after injection. LNs were treated with 1% PFA in PBS
for 10 min, then placed in OCT compound (Tissue-Tek) and frozen in
liquid nitrogen. 8 μm sections were sliced on a Cryostat microtome.
Sections were rehydrated in PBS and stained with 1 μg/mL Hoechst
33242 dye (Invitrogen) for 10 min. After washing, sections were
coverslipped with Roti®-Mount FluorCare (Carl Roth).
2.10. Antigen uptake analysis using bone marrow derived dendritic cells
(BMDCs)
BMDC precursors were harvested from femurs/tibias and were
cultured in RPMI 1640 complete medium (10% FBS, 2 mM L-glutamine,
10 ng/mL GM-CSF, 100 U/mL penicillin, 0.1 mg/mL streptomycin). At
day 3, 50% of medium was replaced. At day 7, BMDCs were harvested
and stored frozen until further use. BMDCs were thawed and placed in
complete medium in 96-well polystyrene V-bottom plates (Greiner)
for 2 h. 105 cells per well were treated with 30, 10, 3.3, 1.11 and
0 μg/mL pHrodo-labeled antigen (Ova, Pap, MN–Ova or MN–Pap) and
uptake was analyzed 10, 30 and 60 min later by ﬂow cytometry.
BMDCs were additionally surface-stained with anti-MHCII (clone M5/
114, BD Pharmingen), anti-CD86 (clone GL1, BioLegend), anti-CD40
(clone HM40-3, eBioscience).To visualize antigen uptake by ﬂuorescence microscopy, BMDCs
were incubated on 8-well cell culture slides (PAA) in complete medium
treated with 20 μg/mL pHrodo–MN–Ova for 1 h, centrifuged and then
ﬁxed with 1% PFA in PBS for 10 min. After washing, cellular nuclei
were again stained with 1 μg/mL Hoechst dye for 10 min.
2.11. Statistical analysis
Statistical signiﬁcance between groups was assessed by Students
T-Test using SigmaStat 2.0 or GraphPad Prism 5.01.
3. Results
3.1. Preparation of neoglycoantigens
Carbohydrate polymer coupling to protein antigens requires the
partial oxidation of the carbohydrate to generate reactive aldehyde
groups for covalent attachment to amine-containing molecules. Brieﬂy,
the carbohydrate polymer is oxidized with sodium periodate and the
newly generated aldehyde groups are used for covalent attachment
to the protein's lysines and 5′amine groups by reduction with
cyanoboroanhydride. The efﬁcacy of aldehyde incorporation upon man-
nan oxidationwas analyzed and displayed a linear correlation of incorpo-
rated aldehyde groups with the amount of sodium periodate used
(Supplementary Fig. S1). As this procedure requires the structural disrup-
tion of single carbohydrate monomers in the mannan polymer, the
oxidized carbohydrates were analyzed for structural integrity by speciﬁc
interaction with ConA, a speciﬁc mannan-binding lectin (Fig. 1A).
Oxidized mannans MN1–MN3 displayed a precipitation curve compara-
ble to mannan, whereas a higher degree of oxidation (MN4) resulted in
complete disruption of the carbohydrate structure as indicated by a
weak ConA interaction, leaving MN1–MN3 as candidates for further
analysis.
The efﬁciency of MN1–MN3 to bind to the protein antigens Ova
and Pap was evaluated using a denaturing SDS-PAGE stained with
coomassie for protein detection (Fig. 1B and E) and Pro-Q Emerald
300 glycoprotein stain for carbohydrate visualization (Fig. 1C and F). In-
creased oxidation of mannan led to increased coupling efﬁcacy for all
proteins tested, but the overall quantitative turnover was strongly de-
pendent on the protein. Whereas coupling of MN1–MN3 to Ova
resulted in partial quantitative conjugation to the proteins (Fig. 1A, B
and C), conjugation to papain led to a complete quantitative turnover
of the protein with MN3 (Fig. 1E and F). Mannan–papain conjugates
barely entered the resolving gel, while the small fraction of mannan–
ovalbumin complexes showed a smear up to over 250 kDa. This hetero-
geneity may mirror the Gaussian distribution of the carbohydrate
size obtained from natural source. Furthermore, especially highly
glycosylated proteins display an aberrant migratory behavior on
SDS-PAGE, because carbohydrates do not bind SDS and the resulting de-
creased charge-to-mass ratio of the protein–SDS complex leads to an in-
creased apparent molecular weight (MW) [20]. The shape of denatured
glycoproteins is also hardly comparable to the partly unglycosylated
sizing standards that contributes additionally to aberrant MW
estimates.
3.2. Characterization of MN–Ova and MN–Pap
Based on coupling efﬁcacy and carbohydrate integrity analysis
using ConA precipitation, Ova- and Pap-conjugates with periodate-
oxidized mannan MN3 were chosen for further analysis and desig-
nated MN–Ova and MN–Pap. As MN–Ova contained a signiﬁcant
amount of unconjugated protein according to the SDS-PAGE data,
the samples were subjected to HPLC using a superdex G75 column
for high-MW conjugate separation. Analysis of Ova revealed two
peaks, a major peak at 37 min, and a small one at 32 min. Coupling
of mannan to Ova left most of the protein unmodiﬁed, but led to a
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Sample fractions 4–10, containing high-MW MN–Ova conjugates
were pooled (Supplementary Fig. S3).
The generation of MN–Pap, using periodate-oxidized mannan MN3
resulted in total conversion of Pap used in the reaction, making further
puriﬁcation steps negligible. At last, both neoglycocomplexes were
separated from unbound mannan by anion exchange chromatography.
To evaluate homogeneity of the samples after puriﬁcation, size char-
acterization was performed via SEC on a Sephacryl S-300 High Resolu-
tion column and DLS; and the ratio of protein to carbohydrate content
in the complexes was assessed (Fig. 1G). SEC data matched SDS-PAGE
data and conﬁrmed the heterogeneity of the neoglycocomplexes.
While the majority (67%) of MN–Pap was composed of complexes
over 450 kDa, MN–Ova contained complexes ranging predominantly
from 45 kDa up to 120 kDa (55%). DLS conﬁrmed the high-MW nature
of MN–Pap (Rh=19.5±4.5 nm), but did not allow for precise MW
estimates, due to the complex carbohydrate–protein content. To evalu-
ate whether covalent attachment of proteins still allowed for structural
mannan recognition, the newly generated neoglycoantigens were
subjected to ConA precipitation (Fig. 1D). MN–Ova and MN–Pap still
displayed speciﬁc interactionwith ConA, proving the integrity of carbo-
hydrates in the complex.
3.3. Impact of carbohydrate variability on neoglycoantigen formation
The impact of carbohydrate variability on neoglycoantigen forma-
tion was assessed by analyzing three additional carbohydrates that
differ in size and origin for their potential to form complexes with Ova
and Pap. Mannan (48 kDa) was compared to two dextrans (40 kDa
[Dex40] and 6 kDa [Dex6]) derived from P. leuconostoc and maltodex-
trin (3.6 kDa), a common food additive. Carbohydrate preparation
was performed according to the protocol established for mannan, and
the oxidation rate of MN3 was also applied to the other carbohydrates.
After covalent coupling, neoglycocomplexes were again analyzed on a
SDS-PAGE (Fig. 2B and E).
Complex-forming capacity demonstrated to be an inherent
feature of the engaged protein molecule. Again, Ova displayed low
complex-forming capacity with all carbohydrates tested, while Pap-
neoglycoconjugates were all of high-MW (Fig. 2B and E). Coupling
dextran (6 kDa) to papain (Dex6–Pap) resulted in precipitation of
neoglycocomplexes that could not be loaded onto SDS-PAGE. Instead,
the supernatant was loaded, which contained only a small percentage of
soluble low-MW complexes (Fig. 2B). Particle formation analysis using
turbiditymeasurements (Fig. 2C) and light obscuration (Fig. 2D) revealed
elevated FNU levels for Dex6–Pap, which are indicative for partial particle
formation. Light obscuration conﬁrmed formation of particles of >25 μm.
Pap-neoglycocomplexes were further subjected to DLS and SEC analyses
and the carbohydrate content was evaluated using the phenol-sulfuric
acid method [15] (Fig. 2A). In comparison to papain, the RH of the MN–
Pap complex increased up to 9-fold (Fig. 1G) and that of MD–Pap and
Dex40–Pap doubled (Fig. 2A). SEC conﬁrmed size distribution of the
Pap-neoglycocomplexes (Fig. 2A).Fig. 1. Analysis of mannan-protein neoglycocomplexes. A) The structural integrity of
mannan after functionalization and (D) in neoglycocomplexes of papain (Pap) or ov-
albumin (Ova) was evaluated via ConA precipitation: Increasing doses (x-axis) of
mannan (MN), its oxidized derivatives (MN1–MN4), or antigen (MN–Ova, Ova,
MN–Pap, Pap) were added to ConA [230 μg/mL] and ODwasmeasured at 405 nm. In-
creasingly oxidized mannans (MN1–MN3) were covalently attached to Ova (B and
C) generating MN–Ova (Ova+MN1–MN3) or Pap (E and F) generating MN–Pap
(Pap+MN1–MN3) and separated by SDS PAGE visualizing protein (B and E) and car-
bohydrate (C and F) content. M = molecular weight size marker. G) shows a table
depicting the protein and carbohydrate content in the neoglycocomplexes and
their indices (carbohydrate/protein) analyzed via OD280 and phenol-sulfuric acid
method [15], respectively. DLS evaluated RH and %RSD; and the size distribution
was assessed by SEC using a Sephacryl S-300 High Resolution column. Size distribu-
tion was calculated in percentage from area under curve of obtained chromatograms
and sizing was categorized in 120–43 kDa, 450–120 kDa and >450 kDa.
Fig. 2. Inﬂuence of carbohydrate variability on neoglycocomplex formation. Panel A de-
picts a table of the protein and carbohydrate content in MD–Pap and Dex40–Pap and
their indices (carbohydrate/protein). RH and %RSD were analyzed via DLS and size dis-
tribution was assessed by SEC. Functionalized dextrans (D40 and D6) and maltodextrin
(MD) were conjugated to Pap (B) or Ova (E), separated, and coomassie stained on a
denaturing SDS-PAGE. Dex6–Pap was further subjected to turbidity measurements
(C) and light obscuration (D).
Fig. 3. Analysis of DCs in cervical dLNs 24 h after intradermal injection of
pHrodo-labeled neoglycocomplexes vs. unmodiﬁed allergens into the mouse ear pin-
nae. Gating strategy to identify MHC-IIhigh DCs (A), further characterized into CD8α
positive and negative DCs (D) as well as quantitation of (here depicted MN–Ova)
pHrodo+ DCs (B). Percentage of MHC-IIhigh and pHrodo+ DCs in dLNs (C). DC sub-
class distribution of pHrodo+ DCs in dLNs (E and F). Data are shown as means±
SEM (n=3). * Pb0.05; ** Pb0.01.
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ed by proteolytic IgG digest (Supplementary Fig. S1A). In comparison to
unmodiﬁed papain activated with (Pap+) or without 5 mM L-cysteine
(Pap−), neoglycocomplexes displayed reduced (MD–Pap and D40–
Pap) or no proteolytic activity (MN–Pap).
Due to the small percentage of generated Ova-neoglycocomplexes,
only MN–Ova has been chosen for further in vivo analysis after SEC
preparation.3.4. Mannan-neoglycoantigens are efﬁciently taken up by resident DCs
We addressed the questionwhether carbohydrate coupling increased
antigen uptake by DCs via C-type lectin receptor targeting. Therefore, the
antigens were labeled with pHrodo Red dye (Invitrogen), a dye that
speciﬁcally ﬂuoresces as pH decreases from neutral to acidic, as provided
in endosomes/lysosomes of cells. In vitro characterization of the cellular
uptake of neoglycocomplexes using bone marrow derived dendritic
cells (BMDCs) demonstrated superior ingestion of mannan-conjugates
MN–Ova andMN–Pap (Supplementary Fig. S4A-D,F). This was conﬁrmed
in vivo by intradermal needle-injection of labeled antigen into the ear
pinnae of mice. Antigen uptake and transport to the ear dLNs were mea-
sured after 24 h by FACS analysis. DCs in cervical LNs were identiﬁed
according to their high expression of MHC class II (Fig. 3A) and addition-
ally characterized by CD8α, CD11b, and CD11c expression and uptake of
pHrodo-labeled antigen (Fig. 3B, D–F). The results showed signiﬁcantly
elevated numbers of pHrodo+MHCIIhigh DCs for mannan conjugates
MN–Ova andMN–Pap (and to a lesser degree forMD–Pap) in comparison
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preferentially to CD8α− DCs, as indicated by an increase in CD8α−/
pHrodo+ DCs compared to unmodiﬁed antigens (Fig. 3E and F). Never-
theless, whether the antigens were taken up in situ by dermal DCs or by
LN resident APCs via the afferent lymphatics could not be fully elucidated.
Histology revealed that antigen-loaded cells in the dLNs were already
present 30 min after intradermal injection (Supplementary Fig. S4G),
suggesting both mechanisms.3.5. Neoglycoantigens display elevated immunogenicity in vivo while
reducing the IgE-inducing capacity
In order to test the efﬁcacy of neoglycoantigens to trigger immunity
in vivo, we targeted dermalDCs in the ear pinnae ofmice by intradermal
injection of low dose antigen. For this purpose, we selected the optimal
candidate from in vitro studies, i.e.mannan-conjugates.
In two independent experiments (Fig. 4), we conﬁrmed the data of
the in vitro studies. Mannan-neoglycoconjugates MN–Ova and MN–PapFig. 4. Humoral immune proﬁle after intradermal immunization of BALB/c mice with
neoglycocomplexes. A–D) Allergen-speciﬁc IgG two weeks after the last immunization
was analyzed via ELISA. Two individual experiments are shown (experiment 1 — A and
B, experiment 2 — C–F). E and F) Biologically functional IgE of experiment 2 was
assessed by RBL assay. Serum dilutions were 1:100 for IgG and 1:17 for IgE. Data are
shown as individual data points (n=3–5). * Pb0.05; ** Pb0.01; *** Pb0.001.displayed superior induction of papain-speciﬁc IgG antibodies, as com-
pared to Ova or Pap-immunized animals (Fig. 4A–D). Antibody subclass
analysis revealed a predominance of IgG1 (data not shown). While
boosting immunogenicity, neoglycocomplexes concomitantly reduced
the allergenicity of the respective allergen, with mannan conjugates
showing the lowest induction of IgE responses (Fig. 4E and F).
Although immunization with MN–Ova induced no circulating
antigen-speciﬁc IgE as detected by the RBL assay (Fig. 4E), ﬂow
cytometric analysis of blood basophils via basophil activation test re-
vealed similar levels of cell bound IgE compared to the unconjugated
antigen (Supplementary Fig. S5E). In contrast, the reduced IgE levels
detected after immunization with MN–Pap (Fig. 4F) could also be con-
ﬁrmed on basophils (Supplementary Fig. S5F).
While humoral immunity was clear-cut at the low antigen dosage
tested, systemic immune responses, as analyzed with spleen cells,
were too weak to elicit measurable results (data not shown).3.6. Carbohydrate conjugates of papain are hypoallergenic
The potential of neoglycoantigens to trigger immediate phase im-
mune responses was analyzed by IgE-mediated degranulation of RBL
cells upon allergen encounter in vitro. RBL cells were incubated with
mouse sera containing high levels of allergen-specifc IgE. The con-
centrations of neoglycoantigens vs. unmodiﬁed antigens to induce
10% of maximal degranulation were determined by titrations (Fig. 5A
and B), and the reduction of allergenic potential was calculated by
dividing the effective concentration of the neoglycoantigen by that of
the unmodiﬁed antigen. Whereas MN–Ova showed no difference
in β-hexosaminidase release compared to unmodiﬁed Ova (1.1-fold
reduction), Pap-neoglycocomplexes displayed an up to 1600-fold re-
duction for MN–Pap, 104-fold for Dex40-Pap, and 21-fold for MD–Pap.Fig. 5. Hypoallergenicity of carbohydrate coupled antigens. IgE-sensitized RBL cells
were stimulated with increasing concentrations of Ova (A) or Pap (B) antigens vs.
neoglycoantigens, and β-hexosaminidase release curves were compared at the 10%-
release log-phase of the Gaussian release curve.
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Targeting antigens to DCs via addressing speciﬁc DC surface mole-
cules demonstrated great potential for enhancing vaccine efﬁcacy [21].
DCs are sentinels and indispensable key players in both, the initiation
and polarization of immune responses, either promoting tolerance or
an appropriate form of immunity [21]. Meanwhile, DCs have been tested
for cancer immunotherapy, using re-infusion of in vitro-generated DCs
loaded with tumor antigen [22]. However, recent advances favor a
much simpler and versatile approach by delivering antigens directly to
DCs in situ [23].
Interesting targets on DCs are receptors of the innate immune
surveillance system that mediate the recognition and uptake of anti-
gens, such as CLR family members (also known as endocytic receptors
or antigen-uptake receptors) [6,24]. These receptors have been demon-
strated to be responsible for the recognition and internalization of
glycosylated self- and foreign antigens, thus leading to antigen presen-
tation on both MHC class I and II molecules.
The present study evaluated the feasibility of carbohydrate-mediated
targeting of allergens to dermal APCs in terms of immunogenicity and al-
lergenicity as potential candidates for SCIT.
We largely focused on mannan, an approximately 48 kDa surface
carbohydrate polymer derived from S. cerevisiae, which was covalently
conjugated to the model allergens Ova and Pap. Mannan and mannose
units have already been successfully used to generate more efﬁcient
immune responses against attached ligands in animal models as well
as in human clinical trials [25–27]. In our study, mannan was function-
alized by reactive aldehyde incorporation via controlled and mild
periodate oxidation followed by covalent attachment to the protein's
amine groups [14] to generate high-MW conjugates. A huge body of
evidence clearly demonstrated a link between protein antigen forma-
tion and the propensity to trigger immunity. Especially high-MWarrays
of protein antigens (multimers>100 kDa) elicited superior humoral
immune responses in comparison to their low-MW, non-aggregated
monovalent form [28]. In this context, multimerization is the key to
immunogenicity, most probably by mimicking repetitive microbial
“patterns” to which our immune system has evolved [29]. Here, we uti-
lized the potential of oxidized mannan and other carbohydrates to act
as multifunctional crosslinking agents, not only to facilitate C-type lec-
tin receptor targeting of our antigenic information, but also to take ad-
vantage of the immunogenicity-enhancing properties of protein
aggregates.
Coupling efﬁcacy turned out to be strongly inﬂuenced by the degree
of oxidation of the functionalized carbohydrate, as well as by the anti-
genic nature of the protein molecule (Fig. 1), leading to large and total
quantitative complex formations for Pap, and to small and considerably
less complex formation for Ova. The integrity of the carbohydrate and of
functional B-cell epitopes was maintained as shown in Figs. 1 and 4.
Coupling efﬁcacy was mainly determined by the protein antigen, as
three other carbohydratemolecules varying in origin and size, including
two dextrans from gram-positive Leuconostoc spp. (40 kDa and 6 kDa)
and the common food additive maltodextrin (3,6 kDa) also showed
weaker coupling efﬁcacy to Ova than to Pap. However, the carbohydrate
moiety had an impact on the size distribution of the resulting com-
plexes (Fig. 2A, B and E).
Coupling of dextran (6 kDa) to papain even resulted in the forma-
tion of microparticles of >25 μm, as demonstrated by light obscuration
(Fig. 2C and D). Partial precipitation of these particles impaired accurate
protein quantiﬁcation, which would be a necessary prerequisite for in
vivo applications. Therefore, this conjugate was excluded from further
experiments.
The observed heterogeneity of complex formation, especially for
papain conjugates, could be due to intramolecular disulﬁde re-bonding
upon re-oxidation after carbohydrate coupling and aldehyde quenching.
While Ova harbors one disulﬁde bond at amino acids (AA) 74–121,
papain carries three (AA155–196, 189–228, and 286–333), and thismay add up to the excellent complex-forming capacity of papain
under the engaged coupling conditions. As covalent attachment of
carbohydrate molecules potentially causes sterical hindrance of the
enzymatic activity of papain, we compared the proteolytic activity of
papain to that of the neoglycoantigens by rat IgG digest (Supplementary
Fig. S1). Carbohydrate attachment to papain strongly diminished (MD–
Pap and Dex40–Pap) or even abrogated (MN–Pap) its proteolytic
activity.
In an in vivo approach we analyzed the ability of neoglycoantigens
to trigger immune responses after intradermal injection. Mannan-
conjugation resulted in strongly elevated numbers of antigen-loaded
DCs in dLNs (Fig. 3C and Supplementary Fig. S4G). Engaging mannan in
this contextmay be superior to other carbohydrate structures as it targets
a variety of mannose receptors such as MR, DC-SIGN and possibly other
PPRs [9]. Further in vitro antigen uptake characterization using BMDCs
(Supplementary Fig. S4A-D,F) substantiated our hypothesis of the superi-
or APC targeting potential and is in accordance with former publications
demonstrating improved processing and presentation of mannosylated
antigens by DCs [2,30].
The pattern of CLR expression varies among the different functional
DC subpopulations [6]. We therefore performed FACS analysis which
revealed that the majority of antigen-loaded DCs were CD8α−
CD11b+CD11c+, a subset belonging to the “myeloid” lineage of DCs
[31]. Myeloid DCs are also known as conventional DCs and are, apart
from plasmacytoid DCs, one of the two main subsets found in mice [31].
Certain DC subsets seem to play an important role in the induction of
allergic inﬂammation and asthma, possibly through their ability to direct
the development of distinct T helper cell populations [32].While CD8α+
cells are prone to induce Th1 differentiation, CD8α− cells preferentially
trigger a Th2 response [33–35]. However, the polarizing capacities of
these DC subsets are not clear-cut and myeloid CD8α− DCs have also
been demonstrated to produce IFN-γ and therefore can trigger a
Th1-biased immune response under conditions of intense immune stim-
ulation such as bacterial or viral infections [36,37].
Intradermal immunization with neoglycoantigens also resulted in
enhanced humoral immune responses (Fig. 4A–D), with MN–Ova and
MN–Pap showing the strongest effects. CLRs demonstrated both, to
induce tolerance [38–40] as well as to enhance immunogenicity in a
context-dependent manner for various infectious diseases and cancer
[9]. Antibody responses measured in these studies were predomi-
nantly of the IgG1 subtype. This is in agreement with our data, as
we could not detect IgG2a antibodies in any group indicating that
CLRs do not promote Th1 polarization in this setting.
With respect to their applicability for allergy immunotherapy,
neoglycoantigens combine two important features, i.e. improving the
immunogenicity and decreasing the allergenic potential of the protein
part of the conjugate (Fig. 4E and F). In this context, we deﬁne the allerge-
nicity of a molecule as the potential to induce a Th2-type response,
resulting in IgE production. This effect is most obvious for mannan-
conjugates that induced signiﬁcantly decreased IgE responses against
the unmodiﬁed allergen. To more closely investigate the IgE-inducing
capacity of our neoglycocomplexes, we isolated basophils from the
blood of immunized animals and determined their activation status
(CD200R up-regulation) upon allergen re-encounter (Supplementary
Fig. S5). Contrasting the RBL data (Fig. 4E), MN–Ova immunization did
not lead to a diminished activation of circulating basophils upon Ova
encounter, while MN–Pap again lacked basophil IgE-sensitizing capacity,
comparable to that of naïve animals. While in the RBL assay, non-
cell-bound allergen-speciﬁc IgGs are washed away before addition of
antigen, which cross-links IgE, antigen stimulation of basophils during
the basophil activation test takes place inwhole blood samples. Therefore,
blocking IgG induced by the vaccination can interfere with cross-linking
of basophil-bound IgE in this assay, a phenomenon well known from
allergen-speciﬁc immunotherapy [41]. Furthermore, neoglycoantigens
also can be considered as hypoallergens in the context of binding to
pre-existing IgE antibodies, which is a major source of side effects during
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hypoallergen, as could be measured with an in vitro IgE-mediated RBL
degranulation assay (Fig. 5A and B), which resulted in a 1600-fold
reduction of IgE binding to the conjugate. Although this effect may be
attributed to the protective masking effect of the carbohydrate moieties
in the high MW complexes of Pap-neoglycocomplexes, it is intriguing
that at the same time, MN–Pap is a potent inducer of IgG responses
(Fig. 4B and D). Recent ﬁndings suggest that IgM+ naïve B cells directly
switch to IgE+ B cells and that IgG1 memory B cells are not a major
source for IgE (i.e. they do not switch to IgE after secondary antigen
encounter) [42], although sequential class switching from IgG1 to IgE
may be required for the generation of high afﬁnity IgE antibodies
[43]. However, this topic is still controversially discussed (also see
[44]). While, immature B cells have been shown to preferentially
class-switch to IgE rather than IgG [45], He et al. have shown that B
cells directly stimulated through CLRs in the absence of T cell help can
induce class switch to IgG and IgA [46]. Together, these ﬁndings provide
a mechanistic insight in how application of neoglycoconjugates may
switch the humoral immune proﬁle from IgE to IgG.
Summing up, our data show that covalent attachment of carbohy-
drates to proteins results in complex-formation of various sizes,
depending on the nature of the antigen as well as the carbohydrate mol-
ecule. The coupling procedure leads to heterogeneous coupling results for
the engaged proteins and future studies will investigate which size range
and carbohydrate to protein ratio are optimal for SIT application, in order
to create individualized and protein tailored coupling protocols. The cou-
pling protocol leaves room for variation, e.g. optimization of Schiff's base
formation via pH alteration and milder aldehyde quenching conditions
using ethanolamine.
Complex formation can reduce the enzymatic activity and IgE binding
capacity of the molecules and can switch the induced antibody proﬁle
from IgE to IgG, but again these effects depend on antigen and carbohy-
drate. The reduced IgE binding capacity of neoglycoprotein conjugates
make these molecules interesting candidates for therapeutic application
in allergic diseases with improved immunogenicity and safety. It is
known that a successful therapeutic outcome in allergy treatment is asso-
ciated with high dose allergen regimes [47], therefore, hypoallergenicity
is a major requirement to improve the safety of allergy vaccines [48]. Es-
pecially, tailored DC targeting with mannan conjugation to antigens rep-
resents an interesting approach for future immunotherapy, allowing the
application of lower allergen dosages and lowering the risk of side effects.
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